Last updated: February 19, 2026
This document provides an analysis of the patent litigation between Evoke Pharma, Inc. and Teva Pharmaceuticals, Inc. concerning Evoke's drug product Gimoti (metoclopramide nasal spray). The case centers on allegations of infringement of Evoke's U.S. Patent No. 9,827,341.
What is the Core of the Litigation?
The litigation concerns Teva Pharmaceuticals' development and potential launch of a generic version of Evoke Pharma's Gimoti, a metoclopramide nasal spray. Evoke alleges that Teva's proposed generic product infringes U.S. Patent No. 9,827,341, which claims a specific pharmaceutical composition and method of use for metoclopramide nasal spray. Evoke seeks to prevent Teva from launching its generic product, arguing it would violate their patent rights.
Who are the Parties Involved?
- Plaintiff: Evoke Pharma, Inc.
- Defendant: Teva Pharmaceuticals, Inc. (and its affiliates, Teva Pharmaceuticals USA, Inc. and Teva Branded Pharmaceutical Products R&D, Inc.)
What is the Patented Technology?
The central patent in this dispute is U.S. Patent No. 9,827,341 (the "'341 Patent"). This patent, titled "Metoclopramide Nasal Spray Formulations and Methods of Use," was issued on November 28, 2017. The patent claims:
- Composition Claims: Specific formulations of metoclopramide nasal spray designed for rapid absorption and efficacy. These formulations often involve specific pH ranges, buffering agents, and preservatives to ensure stability and patient usability.
- Method of Use Claims: Methods for treating conditions such as gastroparesis using the patented nasal spray. These claims focus on the administration of metoclopramide via the nasal route to achieve therapeutic effects.
The '341 Patent is a continuation-in-part of earlier patent applications, establishing a patent family and providing a basis for its claims.
What is Gimoti and its Therapeutic Use?
Gimoti is a prescription nasal spray that contains metoclopramide hydrochloride. It is indicated for the short-term treatment of symptomatic gastroparesis in adults [1]. Gastroparesis is a chronic medical condition characterized by delayed gastric emptying in the absence of a mechanical obstruction in the stomach. Symptoms can include nausea, vomiting, early satiety, bloating, and abdominal pain. Gimoti offers an alternative delivery method for metoclopramide, which has traditionally been administered orally or intravenously.
What are the Allegations of Patent Infringement?
Evoke Pharma alleges that Teva's planned generic metoclopramide nasal spray product directly infringes claims 1, 4, 6, 8, 9, 10, 11, 12, and 13 of the '341 Patent. The infringement allegations are based on Teva's Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) seeking approval for its generic metoclopramide nasal spray product.
Evoke contends that Teva's proposed product falls within the scope of the '341 Patent claims based on its composition and intended use. Specifically, Evoke asserts that Teva's ANDA contains certifications under 21 U.S.C. § 355(b)(2) or § 355(j)(2)(A)(vii) that one or more claims of the '341 Patent are invalid or will not be infringed by the manufacture, use, or sale of Teva's generic product. This type of certification is known as a "paragraph IV" certification under the Hatch-Waxman Act.
What is the Procedural History of the Case?
- Complaint Filed: Evoke Pharma filed its complaint for patent infringement against Teva Pharmaceuticals on September 28, 2022, in the United States District Court for the District of Delaware [2].
- Jurisdiction: The case is brought under the patent laws of the United States, 35 U.S.C. § 1 et seq.
- Demand for Jury Trial: Evoke has demanded a jury trial for all issues so triable.
- Stay of FDA Action: Under the Hatch-Waxman Act, the FDA is stayed from approving Teva's ANDA for 30 months from the date Teva received notice of the infringement suit, unless the court issues a final judgment of non-infringement or invalidity before the 30-month period expires, or the court grants a stay for a longer period. This stay is a critical element for brand-name drug manufacturers like Evoke.
What are the Key Legal Arguments?
Evoke Pharma's arguments focus on demonstrating that Teva's generic product will infringe the '341 Patent. This typically involves:
- Claim Construction: The court will interpret the meaning and scope of the patent claims. This is a critical phase as the outcome directly impacts whether Teva's product falls within the claims.
- Infringement Analysis: Evoke will present evidence that Teva's proposed product, as described in its ANDA and potentially its proposed labeling, incorporates all the limitations of at least one claim of the '341 Patent.
- Validity Challenges: Teva, as the defendant, will likely challenge the validity of the '341 Patent, asserting that it is obvious, not novel, or otherwise invalid under U.S. patent law. This could involve prior art searches and expert testimony.
Teva Pharmaceuticals' defense will likely involve arguments that:
- Its product does not literally infringe the claims of the '341 Patent.
- If the claims are construed broadly enough to cover its product, then the claims are invalid due to prior art.
- Its product operates under the doctrine of equivalents, but this may not be argued if they assert no infringement.
What is the Significance of the Hatch-Waxman Act in this Case?
The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) is fundamental to this litigation. It provides a framework for the approval of generic drugs while protecting the patent rights of brand-name pharmaceutical companies.
Key provisions relevant to this case include:
- ANDA Process: Teva's submission of an ANDA to the FDA is the catalyst for this lawsuit. An ANDA requires the generic applicant to certify that the patent(s) listed in the Orange Book for the brand-name drug are either invalid, unenforceable, or will not be infringed by the generic product.
- Paragraph IV Certification: Teva's likely certification that the '341 Patent is invalid or will not be infringed triggers a 30-month stay of FDA approval. This stay provides brand manufacturers with a period to litigate patent validity and infringement.
- Patent Litigation: The Act incentivizes litigation by granting this 30-month stay, allowing brand companies to defend their market exclusivity. If the brand company prevails, the generic launch is delayed. If the generic company prevails, or the patent is found invalid, the generic can be approved and launched.
What are the Potential Outcomes and Business Implications?
The outcome of this litigation has significant business implications for both Evoke Pharma and Teva Pharmaceuticals.
For Evoke Pharma:
- Successful Defense: If Evoke successfully defends the '341 Patent against Teva's infringement claims and/or invalidity challenges, Teva's ANDA will be delayed. This could preserve Evoke's market exclusivity for Gimoti for a period, allowing it to continue generating revenue from its product without direct generic competition. The duration of this exclusivity would depend on how long the litigation lasts and the potential for further appeals.
- Unsuccessful Defense: If Teva prevails by demonstrating non-infringement or invalidity of the '341 Patent, Teva's ANDA could be approved, leading to the introduction of a generic metoclopramide nasal spray. This would result in significant price erosion for Gimoti and a substantial loss of market share for Evoke.
For Teva Pharmaceuticals:
- Successful Challenge: If Teva successfully navigates the litigation by proving non-infringement or invalidity, it can proceed with launching its generic metoclopramide nasal spray. This would allow Teva to capture a share of the market for this indication and generate revenue from its generic product.
- Unsuccessful Challenge: If Teva fails to overcome the '341 Patent, its generic launch will be delayed. This represents a lost opportunity and potential delay in recouping development costs for its generic product.
Market Impact:
The introduction of a generic competitor typically leads to a sharp decline in the price of the brand-name drug. For Gimoti, this would mean a substantial reduction in revenue for Evoke Pharma, impacting its profitability and potentially its ability to fund future research and development.
Key Takeaways
- Evoke Pharma is suing Teva Pharmaceuticals for infringing U.S. Patent No. 9,827,341, which covers its gastroparesis treatment, Gimoti.
- Teva's generic metoclopramide nasal spray, submitted via an ANDA, is alleged to infringe the '341 Patent.
- The Hatch-Waxman Act is central to the case, granting Evoke a 30-month stay on FDA approval of Teva's ANDA.
- The litigation will focus on patent claim construction, infringement analysis, and patent validity challenges.
- A successful defense by Evoke preserves its market exclusivity; a successful challenge by Teva allows for a generic launch and price erosion.
Frequently Asked Questions
- When was Gimoti first approved by the FDA?
Gimoti was approved by the FDA in September 2018.
- What is the primary indication for Gimoti?
Gimoti is indicated for the short-term treatment of symptomatic gastroparesis in adults.
- What is the duration of the FDA approval stay under the Hatch-Waxman Act?
The stay typically lasts for 30 months from the date Teva received notice of the infringement suit, unless a court decision is rendered sooner.
- What are the main types of claims within U.S. Patent No. 9,827,341?
The patent includes claims directed to pharmaceutical compositions of metoclopramide nasal spray and methods of treating gastroparesis using such compositions.
- Has a trial date been set for this litigation?
As of the filing of this complaint, a trial date had not yet been set. Further court filings would detail scheduling.
Citations
[1] Evoke Pharma, Inc. (2023). Gimoti Prescribing Information. Retrieved from [Evoke Pharma website or FDA database - specific URL would be needed if publicly accessible and stable].
[2] Evoke Pharma, Inc. v. Teva Pharmaceuticals Inc., et al., No. 1:22-cv-02019 (D. Del. Sept. 28, 2022).
